TDS Pharm Co., Ltd. (464280) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for TDS Pharm Co., Ltd. (464280:KRX), powered by AI.

Current Price
₩6,910
P/E Ratio
8.4
Market Cap
35.9B
Sector
Healthcare
What is the TDS Pharm Co., Ltd. stock price forecast?

TDS Pharm Co., Ltd. is currently trading at ₩6,910. View real-time AI analysis on Alpha Lenz.

What is TDS Pharm Co., Ltd. insider trading activity?

View the latest insider trading data for TDS Pharm Co., Ltd. on Alpha Lenz.

What is TDS Pharm Co., Ltd.'s P/E ratio?

TDS Pharm Co., Ltd.'s P/E ratio is 8.4.

TDS Pharm Co., Ltd.

KRX · 464280
₩6,910+410(+6.31%)Market closedKRX regular session 09:00–15:30 KST
Ask about TDS Pharm Co., Ltd.'s future dividend policy...
Alpha Chat Insight

TDS Pharm Co., Ltd. trades at a P/E of 8.4 (undervalued) with solid ROE of 10.5%.

Ask for details

Company Overview

TDS Pharm Co., Ltd. is a prominent player in the pharmaceutical industry, specializing in the research, development, manufacture, and sale of pharmaceutical products. The company plays a critical role in advancing health care by providing essential medications and innovative therapeutic solutions. TDS Pharm focuses on various therapeutic areas including but not limited to oncology, cardiology, and neurology, which are pivotal sectors given the rising demand for specialized health care solutions. The organization's primary function is to deliver high-quality pharmaceuticals that adhere to regulatory standards, ensuring the safety and efficacy of its product offerings. By investing heavily in research and development, TDS Pharm seeks to drive innovation and bring new drugs to the market that can address unmet medical needs. In the financial market, TDS Pharm Co., Ltd. is seen as an influential entity within the pharmaceutical sector, contributing to the overall market health through its robust product pipeline and strategic partnerships. This helps to not only meet global health challenges but also sustain its growth and presence as a key player in the industry.

CEO김철준
SectorHealthcare
IndustryDrug Manufacturers - General
0

Company Statistics

FY 2025

Profile

₩35,945,000,000Market Cap
₩27,620,873,510Revenue
5.53MShares Out
0Employees

Margins

27.17%Gross
19.47%EBITDA
13.63%Operating
18.00%Pre-Tax
15.48%Net

Valuation

8.41P/E
0.84P/B
1.30EV/Sales
7.89EV/EBITDA
-3.95P/FCF

Growth (CAGR)

2.58%Rev 3Yr
8.91%Rev 5Yr
-0.14%Op Inc 3Yr
18.36%Op Inc 5Yr
7.35%Net Inc 3Yr
25.90%Net Inc 5Yr

Returns

8.28%ROA
10.52%ROE
10.06%ROIC

Financial Health

₩1,212,703,750Cash & Cash Equivalents
₩10,154,239,630Net Debt
26.57%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

TDS Pharm Co., Ltd. (ticker: 464280) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - General). Market cap is $35.9B.

The current price is ₩6,910 with a P/E ratio of 8.41x and P/B of 0.84x.

ROE is 10.52% and operating margin is 13.63%. Annual revenue is $27.6B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
TDS Pharm Co., Ltd. (464280) Stock Forecast 2026 ₩6,910 — Price, Financials & Analyst Targets | Alpha Lenz